Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aruna Chakrala

Adolescent Medicine Plainsboro, NJ Medical Doctor

NPI 1447366539 CMS profile 337477

666 Plainsboro Rd, Suite 1020, Plainsboro, NJ 08536

Open in the dashboard

General payments

$1,762

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aruna Chakrala of Plainsboro, NJ is reported in the CMS Open Payments database as having received $1,762 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $179 11
2024 General $102 7
2023 General $440 36
2022 General $647 50
2021 General $359 30
2020 General $24 2
2019 General $11 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aruna Chakrala
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Aruna Chakrala were reported at $179. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.

Show as a table
Year Aruna Chakrala Adolescent Medicine median Middle half National median
2019 $11 $151 $36–$708 $163
2020 $24 $123 $24–$337 $114
2021 $359 $155 $54–$620 $132
2022 $647 $158 $50–$556 $149
2023 $440 $170 $52–$612 $160
2024 $102 $182 $65–$431 $164
2025 $179 $165 $61–$402 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $430 33 payments
  2. Novo Nordisk Inc $420 41 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $243 19 payments
  4. AstraZeneca Pharmaceuticals LP $240 12 payments
  5. Arbor Pharmaceuticals, Inc. $112 10 payments
  6. Abbott Laboratories $79 5 payments
  7. Amgen Inc. $78 6 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $40 3 payments
  9. Exact Sciences Corporation $34 2 payments
  10. Pfizer Inc. $30 2 payments
  11. Other $56 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,741 135 payments
  2. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $339 31 payments
  2. MOUNJARO $337 23 payments
  3. Ozempic $321 30 payments
  4. FARXIGA $227 11 payments
  5. JARDIANCE Diabetes $149 12 payments
  6. Edarbi $112 10 payments
  7. JARDIANCE Diabetes $92 10 payments
  8. Repatha $78 6 payments
  9. Otezla $78 6 payments
  10. TRULICITY $56 4 payments
  11. Other $485 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,860

Median for Internal Medicine: 777

Drug cost

$552,580

Median for Internal Medicine: $73,373

Branded share of claims

27%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 135 $167,413
Ozempic Semaglutide Brand 69 $98,911
Farxiga Dapagliflozin Propanediol Brand 32 $39,345
Januvia Sitagliptin Phosphate Brand 34 $38,250
Rybelsus Semaglutide Brand 28 $38,084
Janumet Sitagliptin Phos/Metformin Hcl Brand 42 $35,878
Linzess Linaclotide Brand 31 $31,208
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 38 $27,844
Jentadueto Linagliptin/Metformin Hcl Brand 13 $11,804
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $11,399

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$123,191

Of which drugs: $10,195

Medicare patients

102

Average age 73

Services billed

2,126

64 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 44%
Ischemic heart disease 34%
Chronic kidney disease 24%
Osteoporosis 21%
Depression 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 23 24 $6,955
Vaccine for Hepatitis B adult dosage (3 dose schedule) injection into muscle 90746 Office 20 28 $1,931
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 16 41 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $38
$38 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $15
$15 32 —
Veozah
  • Astellas Pharma US Inc $14
$14 — —
Wegovy
  • Novo Nordisk Inc $14
$14 — —
NURTEC ODT
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record